(Q43078075)

13 November 2017

Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). (English)

1 reference

13 November 2017

2

1 reference

13 November 2017

6

1 reference

13 November 2017

Anna H Roukens

1

1 reference

13 November 2017

Greet J Boland

series ordinal

3

1 reference

13 November 2017

Willem Verduyn

series ordinal

4

1 reference

13 November 2017

Jaap T van Dissel

series ordinal

5

1 reference

13 November 2017

language of work or name

English

0 references

publication date

28 April 2010

1 reference

13 November 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 November 2017

28

1 reference

13 November 2017

26

1 reference

13 November 2017

4288-4293

1 reference

Hepatitis B Vaccine in Health Care Personnel: Safety, lmmunogenicity, and Indicators of Efficacy

13 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Immunogenetics of the response to HBsAg vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Evaluation of a reduced dose of hepatitis B vaccine administered intradermally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Vaccines for preventing hepatitis B in health-care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Intradermal hepatitis B vaccination: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Virtual DNA analysis--a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Imiquimod; an international update on therapeutic uses in dermatology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.029

10.1016/J.VACCINE.2010.04.029

7 January 2021

Identifiers

DOI

1 reference

13 November 2017

1 reference